Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.

[1]  P. Russo,et al.  Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape , 2022, Genome medicine.

[2]  Guo Ci Teo,et al.  Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. , 2022, Cancer cell.

[3]  Wesley Tansey,et al.  MIRTH: Metabolite Imputation via Rank-Transformation and Harmonization , 2022, Genome Biology.

[4]  P. Puigserver,et al.  Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11 , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Lowe,et al.  A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma. , 2022, Cancer discovery.

[6]  P. Carmeliet,et al.  PHGDH heterogeneity potentiates cancer cell dissemination and metastasis , 2022, Nature.

[7]  J. Rabinowitz,et al.  Spatially resolved isotope tracing reveals tissue metabolic activity , 2022, Nature Methods.

[8]  Indrajeet Patil,et al.  performance: An R Package for Assessment, Comparison and Testing of Statistical Models , 2021, J. Open Source Softw..

[9]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[10]  J. Wolchok,et al.  CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors , 2021, Nature.

[11]  B. Stockwell,et al.  Ferroptosis: mechanisms, biology and role in disease , 2021, Nature Reviews Molecular Cell Biology.

[12]  A. Sidana,et al.  Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. , 2020, The Journal of clinical investigation.

[13]  Amber C. Donahue,et al.  Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.

[14]  M. V. Heiden,et al.  Cell Programmed Nutrient Partitioning in the Tumor Microenvironment , 2020, bioRxiv.

[15]  R. Deberardinis,et al.  1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer , 2020, Science Advances.

[16]  R. Ruslami,et al.  Type 2 Diabetes and its Impact on the Immune System , 2020, Current diabetes reviews.

[17]  M. V. Heiden,et al.  Metabolism in the Tumor Microenvironment , 2020, Annual Review of Cancer Biology.

[18]  J. Moffett,et al.  Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD+ Synthesis During Inflammation and Infection , 2020, Frontiers in Immunology.

[19]  D. Schadendorf,et al.  Metabolic heterogeneity confers differences in melanoma metastatic potential , 2019, Nature.

[20]  Thierry Pourcher,et al.  LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes , 2019, Scientific Reports.

[21]  Angela E. Leek,et al.  A clonal expression biomarker associates with lung cancer mortality , 2019, Nature Medicine.

[22]  Cameron Davidson-Pilon,et al.  lifelines: survival analysis in Python , 2019, J. Open Source Softw..

[23]  Anshul Kundaje,et al.  The ENCODE Blacklist: Identification of Problematic Regions of the Genome , 2019, Scientific Reports.

[24]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[25]  John G Doench,et al.  A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis , 2019, Nature Communications.

[26]  R. Motzer,et al.  Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. , 2019, Cancer discovery.

[27]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[28]  David C. Smith,et al.  Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037) , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  F. S. Yoshikawa,et al.  Role of Histamine in Modulating the Immune Response and Inflammation , 2018, Mediators of inflammation.

[30]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[31]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[32]  R. Davis,et al.  Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. , 2018, Cell metabolism.

[33]  C. Sander,et al.  A Landscape of Metabolic Variation across Tumor Types. , 2018, Cell systems.

[34]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[35]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[36]  Mark W. Ball,et al.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.

[37]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[38]  B. Ogretmen,et al.  Sphingolipid metabolism in cancer signalling and therapy , 2017, Nature Reviews Cancer.

[39]  R. Deberardinis,et al.  Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI. , 2017, JCI insight.

[40]  K. Nutahara,et al.  Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors , 2017, EBioMedicine.

[41]  Ludmila V. Danilova,et al.  Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[42]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[43]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[44]  Chris Sander,et al.  An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.

[45]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[46]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[47]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[48]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[50]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[51]  Lorenzo Galluzzi,et al.  Metabolic control of cell death , 2014, Science.

[52]  Søren Højsgaard,et al.  A Kenward-Roger approximation and parametric bootstrap methods for tests in linear mixed models: The R Package pbkrtest , 2014 .

[53]  G. McVean,et al.  Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.

[54]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[55]  J. Ochocki,et al.  Fructose-1, 6-bisphosphatase opposes renal carcinoma progression , 2014, Nature.

[56]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[57]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[58]  Demin Li,et al.  A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis , 2013, Cancer cell.

[59]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[60]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[61]  Shinichi Nakagawa,et al.  A general and simple method for obtaining R2 from generalized linear mixed‐effects models , 2013 .

[62]  C. Swanton.  Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[63]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[64]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[65]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[66]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[67]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[68]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[69]  M. Martí,et al.  Molecular basis for the substrate stereoselectivity in tryptophan dioxygenase. , 2011, Biochemistry.

[70]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[71]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[72]  Nicolai J. Birkbak,et al.  Chromosomal instability confers intrinsic multidrug resistance. , 2011, Cancer research.

[73]  Klaus Peter Schliep,et al.  phangorn: phylogenetic analysis in R , 2010, Bioinform..

[74]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[75]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[76]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[77]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[78]  Robin Kirschbaum,et al.  Questions and answers , 2009, Diabetes, obesity & metabolism.

[79]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[80]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[81]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[82]  M. Stratton,et al.  Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.

[83]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[84]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[85]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[86]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[87]  M. Fernández,et al.  Impact of Obesity and Metabolic Syndrome on Immunity. , 2016, Advances in nutrition.

[88]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[89]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[90]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[91]  N. King,et al.  Molecules in focus: indoleamine 2,3-dioxygenase. , 2007, The international journal of biochemistry & cell biology.

[92]  Terrence S. Furey,et al.  The UCSC Table Browser data retrieval tool , 2004, Nucleic Acids Res..

[93]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[94]  Markus S. Schröder,et al.  survcomp: an R/Bioconductor package for performance assessment and comparison of survival models , 2011, Bioinform..